<DOC>
	<DOCNO>NCT00642993</DOCNO>
	<brief_summary>The purpose study evaluate effect SCH 497079 weight obese overweight participant . The primary measure effectiveness change body weight treatment . Additional measure include waist circumference body mass index ( BMI ) . In addition , safety SCH 497079 obese overweight participant evaluate . The primary hypothesis treatment SCH 497079 efficacious placebo respect primary efficacy variable .</brief_summary>
	<brief_title>Efficacy Safety Trial Evaluate Effect SCH 497079 Weight Obese Overweight Participants ( Study P05483 ) ( COMPLETED )</brief_title>
	<detailed_description>Following Screening , eligible participant enroll Run-in Period . Participants qualify continuation study accord entry criterion randomize one two treatment group ( SCH 497079 placebo 2:1 ratio ) stratification accord gender . Baseline measurement primary efficacy endpoint , well secondary endpoint evaluate Randomization Visit ( Visit 3 ) . Following randomization , participant treat 12 week double-blind study drug adjunct 500 kcal deficit diet . Participants schedule visit Randomization Visit 2 4 week interval . Each participant encourage adhere medication dietary instruction .</detailed_description>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>&gt; = 18 year age , either sex , race . Obese overweight participant . Participants history major eat disorder , gastrointestinal ( GI ) surgery , active serious cardiovascular , pulmonary , endocrine , neurologic , infectious , GI , hepatic , renal , hematologic , immunologic psychiatric disease diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>